Cancer Biomarkers Funding Opportunities

Titlesort descending Announcement # Expiration Date
Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research PA-18-902 (R01 Clinical Trial Optional) 09/08/2021
Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention PAR-19-252 (R21 Clinical Trial Optional) 11/09/2021
Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention PAR-19-251 (R01 Clinical Trial Optional) 11/09/2021
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research PAR-19-113 (R01 Clinical Trial Optional) 01/08/2022
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer PAR-19-264 (R01 Clinical Trial Optional) 12/11/2021
Notice of Correction to Application Types Allowed for PAR-20-053, Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection NOT-CA-20-067 (R01 Clinical Trial Not Allowed) 01/08/2023
Notice of Special Interest (NOSI): Advancing Head and Neck Cancer Early Detection Research (AHEAD) NOT-CA-20-031 01/08/2022
Notice of Special Interest (NOSI): Single-Cell Proteomics for Interrogating Premalignant and Early Malignant Lesions NOT-CA-20-044 05/08/2023
Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine PAR-18-841 (U24 - Clinical Trial Optional) 06/15/2021
Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection PAR-20-053 (R01 Clinical Trial Not Allowed) 01/08/2023
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes PAR-20-276 (R01 Clinical Trial Not Allowed) 09/08/2022
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes PAR-20-277 (R21 Clinical Trials Not Allowed) 09/08/2022